1. Home
  2. ORKA
  3. ORKA News

Latest Oruka Therapeutics Inc. Common Stock (ORKA) News on October 28, 2025

H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial
ORKA

Insider Monkey

5 months ago

H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference
ORKA

GlobeNewswire

5 months ago

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody
ORKA

GlobeNewswire

5 months ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
ORKA

GlobeNewswire

5 months ago

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference
ORKA

GlobeNewswire

6 months ago

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

We're Not Very Worried About Oruka Therapeutics' (NASDAQ:ORKA) Cash Burn Rate
ORKA

Simply Wall St.

8 months ago

We're Not Very Worried About Oruka Therapeutics' (NASDAQ:ORKA) Cash Burn Rate

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
ORKA

GlobeNewswire

8 months ago

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
ORKA

GlobeNewswire

8 months ago

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Oruka Therapeutics to Present at Multiple March Investor Conferences
ORKA

GlobeNewswire

8 months ago

Oruka Therapeutics to Present at Multiple March Investor Conferences

Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001
ORKA

TipRanks

10 months ago

Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
ORKA

GlobeNewswire

10 months ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
ORKA

GlobeNewswire

10 months ago

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15%
ORKA

Simply Wall St.

a year ago

Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15%

Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference
ORKA

GlobeNewswire

a year ago

Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
ORKA

GlobeNewswire

a year ago

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oruka Therapeutics to Present at Multiple November Investor Conferences
ORKA

GlobeNewswire

a year ago

Oruka Therapeutics to Present at Multiple November Investor Conferences

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
ORKA

GlobeNewswire

a year ago

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Oruka Therapeutics Announces $200 Million Private Placement
ORKA

GlobeNewswire

a year ago

Oruka Therapeutics Announces $200 Million Private Placement

Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19
ORKA

GlobeNewswire

a year ago

Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19

Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
ORKA

GlobeNewswire

a year ago

Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million

Share on Social Networks: